Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.4% – Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) traded down 4.4% during trading on Friday . The company traded as low as $20.77 and last traded at $20.57. 1,723,451 shares traded hands during mid-day trading, an increase of 4% from the average session volume of 1,656,337 shares. The stock had previously closed at $21.53.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ARWR shares. Sanford C. Bernstein lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday. Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Price Performance

The company has a market capitalization of $2.58 billion, a P/E ratio of -4.14 and a beta of 0.97. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The firm’s 50-day moving average is $20.69 and its 200-day moving average is $22.07.

Insider Activity

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the firm’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now directly owns 36,740 shares in the company, valued at $734,800. This trade represents a 7.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,473 shares of company stock valued at $2,937,847 in the last 90 days. Company insiders own 4.50% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $38,000. Values First Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals during the third quarter valued at $52,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares during the last quarter. KBC Group NV lifted its stake in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $149,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.